calcium/magnesium/potassium/sodium oxybatesĭiazepam, calcium/magnesium/potassium/sodium oxybates.Įither increases effects of the other by pharmacodynamic synergism.Monitor closely for signs of respiratory depression and sedation. Limit dosages and durations to the minimum required. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Profound sedation, respiratory depression, coma, and death may result if coadministered. Adjust dose according to prescribing information if needed.Įither increases toxicity of the other by pharmacodynamic synergism. Evaluate for loss of therapeutic effect if medication must be coadministered. Avoid or substitute another drug for these medications when possible. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. apalutamide will decrease the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs that are CYP2C19 substrates can result in lower exposure to these medications.
If not feasible, avoid use of abametapir.Īpalutamide will decrease the level or effect of diazepam by affecting hepatic enzyme CYP2C19 metabolism. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. Buccal soluble film: MonoSol Rx, LLC 30 Technology Drive Warren, New Jersey 07059Ībametapir will increase the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism.SC (Diazepen ): Xeris Pharmaceuticals, Inc 3208 Red River Street, Suite 300 Austin, Texas 78705.El Camino Real, Suite 430 Encinitas, California 92024 Intranasal: Neurelis Pharmaceuticals, Inc 1042-B N.Orphan designations for management of acute repetitive seizures or for Dravet syndrome by various administrative routes (eg, intranasal, buccal soluble film, or SC) Orphan sponsors
Hepatic impairment: 50% of maintenance dose Seizures (Orphan) Renal impairment: No dose adjustment recommended unless administered for prolonged period decrease dose in prolonged periods
IM: 5-10 mg 30 minutes before procedure Preoperative Sedationġ0 mg IM before surgery Sedation in the ICUĥ-10 mg IV 1-2 hours before surgery 0.03-0.1 mg/kg q30min to 6hr Muscle SpasmĢ-10 mg PO q6-8hr PRN, OR 5-10 mg IV/IM initially THEN q3-4hr if necessary Seizure DisorderĠ.2 mg/kg PR, repeat after 4-12 hours PRN Status Epilepticusĥ-10 mg IV/IM q5-10min not to exceed 30 mg, ORĠ.5 mg/kg PR (using parenteral solution), THEN 0.25 mg/kg in 10 minutes PRN Dosage Modifications IV: Titrate dose to 10 mg or less immediately before procedure, not to exceed cumulative dose of 20 mg reduce dose of narcotic by one third or omit, OR Initial: 10 mg IV/IM, may give additional doses of 5-10 mg IV q6-8hr as needed Endoscopy Dosage Forms & Strengths tablet: Schedule IVĢ-10 mg PO q6-12hr, OR 2-10 mg IV/IM q6-12hr no more than 30 mg/8 hours Alcohol Withdrawalġ0 mg PO q6-8hr during first 24hr reduce to 5 mg PO q6-8hr PRN
0 kommentar(er)
